Choreo LLC Purchases 2,702 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Choreo LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 249.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,785 shares of the biopharmaceutical company’s stock after buying an additional 2,702 shares during the quarter. Choreo LLC’s holdings in Regeneron Pharmaceuticals were worth $4,000,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Gilbert & Cook Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 8.3% in the fourth quarter. Gilbert & Cook Inc. now owns 1,907 shares of the biopharmaceutical company’s stock valued at $1,675,000 after buying an additional 146 shares during the last quarter. Principal Securities Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $280,000. AGF Management Ltd. acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $639,000. Qsemble Capital Management LP bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $210,000. Finally, Envestnet Portfolio Solutions Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 45.2% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 1,188 shares of the biopharmaceutical company’s stock valued at $1,043,000 after purchasing an additional 370 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on REGN shares. Barclays boosted their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. TD Cowen raised their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Argus boosted their price target on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Truist Financial reaffirmed a “buy” rating and issued a $1,200.00 price objective (up from $1,135.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 2nd. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,109.70.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $1,144.77 on Tuesday. The stock has a market capitalization of $126.20 billion, a price-to-earnings ratio of 33.82, a PEG ratio of 3.86 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 12 month low of $769.19 and a 12 month high of $1,211.20. The firm has a fifty day simple moving average of $1,114.85 and a 200 day simple moving average of $1,021.92. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. During the same quarter last year, the company earned $8.79 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% compared to the same quarter last year. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now directly owns 17,882 shares in the company, valued at $18,941,329.68. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The disclosure for this sale can be found here. Insiders have sold 11,561 shares of company stock valued at $13,095,105 in the last 90 days. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.